Movement Alert｜THE CIGNA GROUP Falls 3.07% in Regular Trading, Raymond James Downgrades Rating to Outperform

Market Focus08-04

On August 4, THE CIGNA GROUP fell 3.07% in regular trading, trading at $273.385/share, with turnover of $85.90 million. The decline was triggered by Raymond James downgrading the stock from Strong Buy to Outperform, while cutting its price target from $350 to $320.

Raymond James noted that while Cigna's valuation remains attractive, slowing business growth combined with persistent headwinds in its pharmacy benefit management operations leaves the stock without clear near-term upside catalysts. The firm highlighted that although Cigna's Q2 earnings beat expectations with adjusted EPS of $7.78 versus the $7.60 consensus estimate and revenue of $71.56 billion topping the $70.34 billion forecast, management confirmed during the earnings call that GLP-1 prescription growth is moderating, pressuring the pharmacy business.

Multiple analysts maintain bullish stances, with Goldman Sachs raising its target to $352, Guggenheim to $361, and UBS maintaining a $400 target. However, the broader Health Care Services sector also showed weakness, with DaVita down 2.0% and CVS Health down 1.47%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117943163?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 22:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117943163","market":"us","top_or_hot":-1,"title":"Movement Alert｜THE CIGNA GROUP Falls 3.07% in Regular Trading, Raymond James Downgrades Rating to Outperform","media":"Market Focus","content":"<p><p>On August 4, THE CIGNA GROUP fell 3.07% in regular trading, trading at $273.385/share, with turnover of $85.90 million. The decline was triggered by Raymond James downgrading the stock from Strong Buy to Outperform, while cutting its price target from $350 to $320.</p><p>Raymond James noted that while Cigna's valuation remains attractive, slowing business growth combined with persistent headwinds in its pharmacy benefit management operations leaves the stock without clear near-term upside catalysts. The firm highlighted that although Cigna's Q2 earnings beat expectations with adjusted EPS of $7.78 versus the $7.60 consensus estimate and revenue of $71.56 billion topping the $70.34 billion forecast, management confirmed during the earnings call that GLP-1 prescription growth is moderating, pressuring the pharmacy business.</p><p>Multiple analysts maintain bullish stances, with Goldman Sachs raising its target to $352, Guggenheim to $361, and UBS maintaining a $400 target. However, the broader Health Care Services sector also showed weakness, with DaVita down 2.0% and CVS Health down 1.47%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜THE CIGNA GROUP Falls 3.07% in Regular Trading, Raymond James Downgrades Rating to Outperform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜THE CIGNA GROUP Falls 3.07% in Regular Trading, Raymond James Downgrades Rating to Outperform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-04 22:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 4, THE CIGNA GROUP fell 3.07% in regular trading, trading at $273.385/share, with turnover of $85.90 million. The decline was triggered by Raymond James downgrading the stock from Strong Buy to Outperform, while cutting its price target from $350 to $320.</p><p>Raymond James noted that while Cigna's valuation remains attractive, slowing business growth combined with persistent headwinds in its pharmacy benefit management operations leaves the stock without clear near-term upside catalysts. The firm highlighted that although Cigna's Q2 earnings beat expectations with adjusted EPS of $7.78 versus the $7.60 consensus estimate and revenue of $71.56 billion topping the $70.34 billion forecast, management confirmed during the earnings call that GLP-1 prescription growth is moderating, pressuring the pharmacy business.</p><p>Multiple analysts maintain bullish stances, with Goldman Sachs raising its target to $352, Guggenheim to $361, and UBS maintaining a $400 target. However, the broader Health Care Services sector also showed weakness, with DaVita down 2.0% and CVS Health down 1.47%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CI","symbol_name":"信诺保险","start_time":0,"source_url":"","article_id":"1117943163","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117943163","pubTimestamp":1785852876,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 4, THE CIGNA GROUP fell 3.07% in regular trading, trading at $273.385/share, with turnover of $85.90 million. The decline was triggered by Raymond James downgrading the stock from Strong...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CI":"信诺保险"},"translate_title":"走势警报|信诺集团常规交易下跌3.07%，Raymond James将评级下调至跑赢大盘","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CI":1},"content_text":"On August 4, THE CIGNA GROUP fell 3.07% in regular trading, trading at $273.385/share, with turnover of $85.90 million. The decline was triggered by Raymond James downgrading the stock from Strong Buy to Outperform, while cutting its price target from $350 to $320.Raymond James noted that while Cigna's valuation remains attractive, slowing business growth combined with persistent headwinds in its pharmacy benefit management operations leaves the stock without clear near-term upside catalysts. The firm highlighted that although Cigna's Q2 earnings beat expectations with adjusted EPS of $7.78 versus the $7.60 consensus estimate and revenue of $71.56 billion topping the $70.34 billion forecast, management confirmed during the earnings call that GLP-1 prescription growth is moderating, pressuring the pharmacy business.Multiple analysts maintain bullish stances, with Goldman Sachs raising its target to $352, Guggenheim to $361, and UBS maintaining a $400 target. However, the broader Health Care Services sector also showed weakness, with DaVita down 2.0% and CVS Health down 1.47%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117943163","isCrawlerRequest":true}